



Our STN: BL 125730/116

SUPPLEMENT APPROVAL

January 30, 2024

Stratatech Corporation
Attention: Peggy Rooney
Senior Manager - Regulatory Affairs Strategy
150 Charmany Drive, Suite 150
Madison, WI 53719

Dear Peggy Rooney:

We have approved your request received August 1, 2023, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat (STRATAGRAFT), to update the Warning and Precautions and Use in Specific Populations sections of the US Prescribing Information (USPI) and the relevant sections of the patient package insert (PPI) to reflect changes in the xenotransplantation product requirements for STRATAGRAFT.

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling Package Insert submitted under amendment 1, dated January 29, 2024; Patient Package Insert submitted under amendment 1, dated January 29, 2024; and the draft carton and container labels submitted under amendment 0, dated August 1, 2023.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert and Patient Package Insert, submitted on January 29, 2024. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on January 29, 2024, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125730 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Tejashri Purohit-Sheth, MD
Director
Division of Clinical Evaluation General Medicine
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research